Reata Pharmaceuticals, Inc. 2R3.F Stock
Reata Pharmaceuticals, Inc. Price Chart
Reata Pharmaceuticals, Inc. 2R3.F Financial and Trading Overview
Reata Pharmaceuticals, Inc. stock price | 161 EUR |
Previous Close | 92.5 EUR |
Open | 84.5 EUR |
Bid | 84.5 EUR x 60000 |
Ask | 86.5 EUR x 50000 |
Day's Range | 84.5 - 84.5 EUR |
52 Week Range | 18.7 - 95.5 EUR |
Volume | 10 EUR |
Avg. Volume | 0 EUR |
Market Cap | 3.58B EUR |
Beta (5Y Monthly) | 1.515845 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 226.44 EUR |
2R3.F Valuation Measures
Enterprise Value | 3.33B EUR |
Trailing P/E | N/A |
Forward P/E | -9.735023 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 2388.827 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 2222.318 |
Enterprise Value/EBITDA | -10.289 |
Trading Information
Reata Pharmaceuticals, Inc. Stock Price History
Beta (5Y Monthly) | 1.515845 |
52-Week Change | 224.13% |
S&P500 52-Week Change | 20.43% |
52 Week High | 95.5 EUR |
52 Week Low | 18.7 EUR |
50-Day Moving Average | 85.63 EUR |
200-Day Moving Average | 50.52 EUR |
2R3.F Share Statistics
Avg. Volume (3 month) | 0 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 33.04M |
Float | 26.69M |
Short Ratio | N/A |
% Held by Insiders | 3.82% |
% Held by Institutions | 101.73% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -21673.34% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -35.78% |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 1.5M EUR |
Revenue Per Share (ttm) | 0.04 EUR |
Quarterly Revenue Growth (yoy) | -78.70% |
Gross Profit (ttm) | -167627000 EUR |
EBITDA | -323340000 EUR |
Net Income Avi to Common (ttm) | -354176000 EUR |
Diluted EPS (ttm) | -8.48 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 320.96M EUR |
Total Cash Per Share (mrq) | 8.55 EUR |
Total Debt (mrq) | 117.93M EUR |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 6.091 |
Book Value Per Share (mrq) | -3.482 |
Cash Flow Statement
Operating Cash Flow (ttm) | -227531008 EUR |
Levered Free Cash Flow (ttm) | -143585376 EUR |
Profile of Reata Pharmaceuticals, Inc.
Country | Germany |
State | TX |
City | Plano |
Address | 5320 Legacy Drive |
ZIP | 75024 |
Phone | 972 865 2219 |
Website | https://www.reatapharma.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 321 |
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.
Q&A For Reata Pharmaceuticals, Inc. Stock
What is a current 2R3.F stock price?
Reata Pharmaceuticals, Inc. 2R3.F stock price today per share is 161 EUR.
How to purchase Reata Pharmaceuticals, Inc. stock?
You can buy 2R3.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Reata Pharmaceuticals, Inc.?
The stock symbol or ticker of Reata Pharmaceuticals, Inc. is 2R3.F.
Which industry does the Reata Pharmaceuticals, Inc. company belong to?
The Reata Pharmaceuticals, Inc. industry is Biotechnology.
How many shares does Reata Pharmaceuticals, Inc. have in circulation?
The max supply of Reata Pharmaceuticals, Inc. shares is 38.51M.
What is Reata Pharmaceuticals, Inc. Price to Earnings Ratio (PE Ratio)?
Reata Pharmaceuticals, Inc. PE Ratio is 0.00000000 now.
What was Reata Pharmaceuticals, Inc. earnings per share over the trailing 12 months (TTM)?
Reata Pharmaceuticals, Inc. EPS is 0 EUR over the trailing 12 months.
Which sector does the Reata Pharmaceuticals, Inc. company belong to?
The Reata Pharmaceuticals, Inc. sector is Healthcare.